26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Chromoblastomycosis is a slow-progressing, granulomatous, suppurative fungal infection caused by the traumatic inoculation of melanised fungi into subcutaneous and transcutaneous tissues, leading to morbidity and work inactivity. The most clinically isolated agents are the species F. pedrosoi, C. carrioni, followed by P. verrucosa, E. dermatitidis and R. aquaspersa. It has a worldwide distribution and prevalence in underdeveloped regions of the world, where compulsory reporting of cases is non-existent. In Brazil, it is prevalent in the Amazon region, where Pará leads the country in cases of…mehr

Produktbeschreibung
Chromoblastomycosis is a slow-progressing, granulomatous, suppurative fungal infection caused by the traumatic inoculation of melanised fungi into subcutaneous and transcutaneous tissues, leading to morbidity and work inactivity. The most clinically isolated agents are the species F. pedrosoi, C. carrioni, followed by P. verrucosa, E. dermatitidis and R. aquaspersa. It has a worldwide distribution and prevalence in underdeveloped regions of the world, where compulsory reporting of cases is non-existent. In Brazil, it is prevalent in the Amazon region, where Pará leads the country in cases of the disease. In the clinical analyses laboratory of the clinical mycology reference hospital Hospital Universitário Lauro Wanderley (HULW/EBSERH), Paraíba, Brazil, various diagnoses of the disease are found, and there has been one scientifically described case report to date. The aim of this study was to review the literature on the subject with an emphasis on updating data on the clinical, taxonomic, laboratory, epidemiological and therapeutic aspects of cases of chromoblastomycosis in Brazil and worldwide.
Autorenporträt
Professor of Clinical Mycology at the Department of Pharmaceutical Sciences/UFPB. Graduated in Pharmacy and Clinical Analysis from UFPB; Specialisation in Clinical Microbiology from the Brazilian Society of Microbiology; PhD in Pharmacology from the Natural and Synthetic Bioactive Products programme (concept 6 CAPES).